Bob Tepper, M.D., R&D president, is leaving Millennium in the first quarter of 2007. Dr. Tepper was one of the founding executives in 1994 and was an integral part of its expansion from a drug discovery company to a fully-integrated biopharmaceutical company with nine novel molecules in development and market-leading product, Velcade for Injection for relapsed multiple myeloma and mantle cell lymphoma.

"Bob was one of a small group of people who had a vision for forming a new company that could make a difference in the way medicine is discovered to change the lives of patients," said Millennium president and chief executive officer Deborah Dunsire, M.D. "Today that vision is a reality and Millennium is indeed improving the lives of patients with multiple myeloma and mantle cell lymphoma, with a strong and diverse pipeline behind Velcade. I would like to thank Bob for his vision and relentless commitment to scientific excellence."